Related Experiment Videos
Calcium antagonists in the treatment of hypertension. An overview
1St. Paul Medical Center, Dallas.
Insights
Calcium antagonists effectively manage hypertension by lowering blood pressure while preserving microcirculatory blood flow. Different agents like nifedipine, verapamil, and diltiazem offer unique benefits for various hypertension types and patient needs.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Calcium antagonists represent a significant therapeutic advancement for hypertension management.
- These drugs effectively reduce blood pressure in hypertensive patients.
- They also help maintain blood flow within the microcirculation.
Purpose of the Study:
- To compare the hemodynamic and pharmacologic actions of various calcium antagonists.
- To evaluate their efficacy in different hypertension scenarios.
- To assess their safety profile compared to other antihypertensives.
Main Methods:
- Review of existing clinical data and pharmacological studies on calcium antagonists.
- Comparative analysis of nifedipine, verapamil, and diltiazem.
- Assessment of effects on blood pressure, heart rate, and microcirculatory flow.
Main Results:
- Nifedipine is effective for severe and refractory hypertension; long-acting formulations may mitigate reflex tachycardia.
- Verapamil and diltiazem are suitable for mild-to-moderate chronic hypertension, with neutral or slightly reduced heart rate effects.
- Calcium antagonists exhibit a favorable biochemical profile, avoiding adverse effects associated with diuretics and some beta-blockers.
Conclusions:
- Calcium antagonists offer diverse therapeutic options for hypertension management.
- Specific agents like nifedipine, verapamil, and diltiazem have distinct clinical applications.
- Long-acting formulations are emerging to improve patient compliance and treatment simplicity.
Abstract:
The availability of calcium antagonists has provided yet another therapeutic option in the management of hypertension. Calcium antagonists lower the blood pressure in hypertensive individuals while preserving the blood flow at the microcirculatory level. While all the available calcium antagonists are effective in the treatment of hypertension, they differ in their hemodynamic and pharmacologic actions. Nifedipine appears to be suitable for immediate treatment of severe hypertension and for chronic treatment of uncomplicated or refractory hypertension. In some but not all patients, co-administration of a beta-blocker is necessary to blunt reflex tachycardia. This problem is less likely with the tablet/long-acting formulation of nifedipine. Verapamil and diltiazem are useful as initial therapy for chronic mild-to-moderate hypertension. They are as effective as other first-line drugs in the treatment of uncomplicated hypertension. The heart rate with verapamil or diltiazem does not change or is slightly reduced, thus contrasting with nifedipine. Experience to date suggests that calcium antagonists do not cause adverse biochemical effects and in this respect are superior to diuretics and certain beta-blockers. Currently, verapamil is available as a sustained release preparation. In the near future, nifedipine or diltiazem may also be available in the long acting formulation to permit simplicity and to enhance patient compliance in the treatment of hypertension.